ClinicalTrials.gg
TerminatedNCT00329108ZOOMUpdated Mar 29, 2021Results posted

Ziprasidone And Olanzapine's Outcomes In Mania

A Phase 4 interventional study of ziprasidone hydrochloride and olanzapine in Acute Mania and Bipolar Disorder, Manic, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-03-29.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Please see Brief Summary for Termination Reason.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ziprasidone in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. ziprasidone · Bipolar Disorder.

Enrollment
17th of 28
29 · median 39
Started
2006
with 8 others
Phase 4
11 of 28
none open now
Registered
10th of 28
by date
Lead sponsor
14 of 28
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 28 studies testing ziprasidone in Bipolar Disorder, this one is the 17th largest by enrollment, is one of 9 that started in 2006, is one of 11 in phase 4, and was the 10th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 28 studies testing ziprasidone in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About ziprasidone

ziprasidone: first FDA approval 2001 (GEODON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing ziprasidone in Bipolar Disorder as a file.
02

Study summary

The purpose of this study is to compare the efficacy and tolerability of ziprasidone versus olanzapine in the treatment of acute mania. An open label extension will further evaluate the efficacy, safety, and tolerability of ziprasidone compared with olanzapine. Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on July 30, 2007. Subjects that were enrolled at the time completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment. The Last Subject Last Visit was January 10, 2008.

03

Conditions studied

  • Acute Mania
  • Bipolar Disorder, Manic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a primary diagnosis of Bipolar I Disorder, current episode manic ( 296.4x) or mixed (DSM-IV296.6x) as determined by a structured clinical interview (Mini International Neuropsychiatric Interview (MINI)) at screening.
  • A minimum score of 20 on the YMRS (Youngs Mania Rating Scale).

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of learning disability or organic brain syndrome.
  • Have a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    A

    Drug: ziprasidone hydrochloride

  • Active comparator
    B

    Drug: olanzapine

Interventions

  • Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.

    Also known as: Geodon, Zeldox

  • Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.

06

What researchers measure

Primary outcomes

  1. Mean Reduction in Young Mania Rating Scale (YMRS) Score During the Double Blind Phase.

    YMRS is 11-item instrument with scales between 0 to 4 for 7 items and scales between 0 and 8 for 4 items. 0 is normal and either 4 or 8 is the highest level of abnormal, depending on the item.

    Time frame: 4 weeks

Secondary outcomes

  1. Change From Baseline in Clinical Global Impressions Scale for Use in Bipolar Illness Scores; Montgomery Asberg Depression Scale Scores in the Double Blind Phase.

    Time frame: up to 10 weeks

  2. Change From Baseline in Global Assessment of Functioning Scale Scores, Treatment Satisfaction Questionnaire for Medication, Quality of Life Enjoyment and Satisfaction Questionnaire in the Double Blind Phase.

    Time frame: 6 months

  3. Percentage of Patients With Symptomatic Remission After 4, 6 and 10 Weeks of Treatment and at the End of the Double-blind Phase.

    Time frame: 4, 6 and 10 weeks

  4. Time to Symptomatic Remission in the Double Blind Phase.

    Time frame: up to 10 weeks

  5. Percentage of Patients With Clinical Response After 6 Weeks of Double-blind Treatment.

    Time frame: 6 weeks

  6. Percentage of Patients With Symptomatic Relapse of Mania and/or Symptomatic Relapse of Depression During the Open Label Phase.

    Time frame: 6 months

07

Results

Posted Mar 13, 2009
Limitations and caveats
The study was terminated due to poor recruitment. No efficacy data were summarized due to very low sample size. Only safety data were summarized.

Participant flow

47 centers in Europe.

Participant flow — Overall Study
MilestoneZiprasidoneOlanzapine
Started1514
Completed52
Not completed1012
Withdrew: Adverse event22
Withdrew: Lack of efficacy33
Withdrew: Withdrawal by subject02
Withdrew: Symptomatic deterioration11
Withdrew: Subject no longer willing to participate22
Withdrew: Study terminated by sponsor10
Withdrew: Withdrew patient after sae resolved10
Withdrew: Protocol violation02

Outcome measures

PrimaryMean Reduction in Young Mania Rating Scale (YMRS) Score During the Double Blind Phase.

YMRS is 11-item instrument with scales between 0 to 4 for 7 items and scales between 0 and 8 for 4 items. 0 is normal and either 4 or 8 is the highest level of abnormal, depending on the item.

Time frame:
4 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Clinical Global Impressions Scale for Use in Bipolar Illness Scores; Montgomery Asberg Depression Scale Scores in the Double Blind Phase.
Time frame:
up to 10 weeks

Results for this outcome have not been posted.

SecondaryChange From Baseline in Global Assessment of Functioning Scale Scores, Treatment Satisfaction Questionnaire for Medication, Quality of Life Enjoyment and Satisfaction Questionnaire in the Double Blind Phase.
Time frame:
6 months

Results for this outcome have not been posted.

SecondaryPercentage of Patients With Symptomatic Remission After 4, 6 and 10 Weeks of Treatment and at the End of the Double-blind Phase.
Time frame:
4, 6 and 10 weeks

Results for this outcome have not been posted.

SecondaryTime to Symptomatic Remission in the Double Blind Phase.
Time frame:
up to 10 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Patients With Clinical Response After 6 Weeks of Double-blind Treatment.
Time frame:
6 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Patients With Symptomatic Relapse of Mania and/or Symptomatic Relapse of Depression During the Open Label Phase.
Time frame:
6 months

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ziprasidone———
Olanzapine———
Most frequent serious events
Most frequent serious events
EventZiprasidoneOlanzapine
Oculogyric crisisEye disorders1/150/14
Disease progressionGeneral disorders1/150/14
laryngospasmRespiratory, thoracic and mediastinal disorders1/150/14
Most frequent other events
Showing 10 of 34
Most frequent other events
EventZiprasidoneOlanzapine
tremorNervous system disorders1/153/14
somnolenceNervous system disorders3/151/14
Dry mouthGastrointestinal disorders0/152/14
fatigueGeneral disorders0/152/14
increased appetiteMetabolism and nutrition disorders0/152/14
insomniaPsychiatric disorders2/150/14
AnemiaBlood and lymphatic system disorders0/151/14
HyperprolactinaemiaEndocrine disorders0/151/14
flatulenceGastrointestinal disorders0/151/14
gingivitisGastrointestinal disorders0/151/14

Baseline characteristics

Age, Customized
Age, Customized(participants)ZiprasidoneOlanzapineTotal
18-44 years9716
45-64 years6713
Sex: Female, Male
Sex: Female, Male(Participants)ZiprasidoneOlanzapineTotal
Female10515
Male5914
08

Study locations

19 sites
  • Pfizer Investigational Site
    Aachen, 52074, Germany
  • Pfizer Investigational Site
    Augsburg, 86156, Germany
  • Pfizer Investigational Site
    Freiburg, 79104, Germany
  • Pfizer Investigational Site
    Athens, 124 62, Greece
  • Pfizer Investigational Site
    S. Arsenio, Salerno 84037, Italy
  • Pfizer Investigational Site
    Bari, 70100, Italy
  • Pfizer Investigational Site
    Guardiagrele (CH), 66016, Italy
  • Pfizer Investigational Site
    Lido Di Camaiore (LU), 55043, Italy
  • Pfizer Investigational Site
    Partinico (Pa), 90047, Italy
  • Pfizer Investigational Site
    Perugia, 06127, Italy
  • Pfizer Investigational Site
    Siena, 53100, Italy
  • Pfizer Investigational Site
    Torino, 10126, Italy
  • Pfizer Investigational Site
    Trieste, 34126, Italy
  • Pfizer Investigational Site
    Terrassa, Barcelona 08227, Spain
  • Pfizer Investigational Site
    Alava, Vitoria 01004, Spain
  • Pfizer Investigational Site
    Granada, 18014, Spain
  • Pfizer Investigational Site
    Malaga, 29009, Spain
  • Pfizer Investigational Site
    Ankara, 06100, Turkey
  • Pfizer Investigational Site
    Istanbul, 34440, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Jul 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2009, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2006
First posted
May 24, 2006
Start
Nov 2006
Primary completionActual
Jul 2007
CompletionActual
Jan 2008
Results first posted
Mar 13, 2009
Last update
Mar 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00329108
Responsible party
Sponsor
First posted
May 24, 2006
Start date
Nov 2006
Primary completion
Jul 2007
Completion
Jan 2008
Results posted
Mar 13, 2009
Last update
Mar 29, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziprasidone

Start the discussion